$ENTO
Entero Therapeutics Inc

2023 Q3 Form 10-Q Financial Statement

#000141057823001882 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.420M $2.829M
YoY Change -16.68% 13.19%
% of Gross Profit
Research & Development $1.011M $1.353M
YoY Change 27.81% -53.45%
% of Gross Profit
Depreciation & Amortization $7.300K $7.300K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $3.433M $4.182M
YoY Change -178.21% -22.65%
Operating Profit -$3.433M -$4.182M
YoY Change -178.21% -22.65%
Interest Expense $1.250K $5.178K
YoY Change 44.84% 60.91%
% of Operating Profit
Other Income/Expense, Net -$1.021K -$7.588K
YoY Change -156.69% 231.06%
Pretax Income -$3.430M -$4.189M
YoY Change -178.11% -22.54%
Income Tax
% Of Pretax Income
Net Earnings -$3.434M -$4.189M
YoY Change -178.2% -22.54%
Net Earnings / Revenue
Basic Earnings Per Share -$0.46 -$1.89
Diluted Earnings Per Share -$0.46 -$1.89
COMMON SHARES
Basic Shares Outstanding 7.152M 1.814M
Diluted Shares Outstanding 7.566M 2.271M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.290M $1.236M
YoY Change 98.55% 7.02%
Cash & Equivalents $3.300M $1.200M
Short-Term Investments
Other Short-Term Assets $680.0K $1.118M
YoY Change -2.88% 98.3%
Inventory
Prepaid Expenses $684.3K $1.118M
Receivables
Other Receivables
Total Short-Term Assets $3.977M $2.354M
YoY Change 56.0% 31.56%
LONG-TERM ASSETS
Property, Plant & Equipment $21.88K $29.20K
YoY Change -57.22% -50.06%
Goodwill $1.684M $1.684M
YoY Change -1.78% -4.08%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $32.77K
YoY Change -46.24% -4.54%
Total Long-Term Assets $1.951M $1.974M
YoY Change -6.95% -7.67%
TOTAL ASSETS
Total Short-Term Assets $3.977M $2.354M
Total Long-Term Assets $1.951M $1.974M
Total Assets $5.927M $4.328M
YoY Change 27.59% 10.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $579.3K $1.591M
YoY Change -83.83% -59.88%
Accrued Expenses $834.5K $479.9K
YoY Change 206.51% 12.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $153.5K
YoY Change -5.21%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.482M $3.261M
YoY Change -62.92% -81.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $170.0K $184.7K
YoY Change -26.5% -77.84%
Total Long-Term Liabilities $170.0K $184.7K
YoY Change -26.5% -77.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.482M $3.261M
Total Long-Term Liabilities $170.0K $184.7K
Total Liabilities $2.648M $3.446M
YoY Change -61.76% -80.98%
SHAREHOLDERS EQUITY
Retained Earnings -$180.2M -$176.8M
YoY Change 9.54% 4.68%
Common Stock $1.346K $421.00
YoY Change 482.68% -81.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.279M $882.0K
YoY Change
Total Liabilities & Shareholders Equity $5.927M $4.328M
YoY Change 27.59% 10.2%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.434M -$4.189M
YoY Change -178.2% -22.54%
Depreciation, Depletion And Amortization $7.300K $7.300K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$3.330M -$2.762M
YoY Change -21.72% -39.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.390M 1.933M
YoY Change 12.96% 2431.49%
NET CHANGE
Cash From Operating Activities -3.330M -2.762M
Cash From Investing Activities
Cash From Financing Activities 5.390M 1.933M
Net Change In Cash 2.060M -828.4K
YoY Change 297.94% -81.63%
FREE CASH FLOW
Cash From Operating Activities -$3.330M -$2.762M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4208995
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
995003
dei Entity Registrant Name
EntityRegistrantName
First Wave BioPharma, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001604191
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4208995
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
995003
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37853
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4993860
dei Entity Address Address Line1
EntityAddressAddressLine1
777 Yamato Road, Suite 502
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
dei City Area Code
CityAreaCode
561
dei Local Phone Number
LocalPhoneNumber
589-7020
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
FWBI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7152204
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176793574
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1236054
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1362910
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
93014
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1117737
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1956831
CY2023Q2 us-gaap Assets Current
AssetsCurrent
2353791
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3412755
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29202
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43839
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
21519
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
21513
CY2023Q2 us-gaap Goodwill
Goodwill
1684182
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
227927
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
259261
CY2023Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
11250
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
18149
CY2023Q2 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1944878
CY2022Q4 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1983105
CY2023Q2 us-gaap Assets
Assets
4327871
CY2022Q4 us-gaap Assets
Assets
5439699
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1591195
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
720040
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
479862
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320176
CY2023Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
943243
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
761488
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
153478
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
603494
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
63564
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
66151
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
29907
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12138
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3261249
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2483487
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
184662
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
214060
CY2023Q2 us-gaap Liabilities
Liabilities
3445911
CY2022Q4 us-gaap Liabilities
Liabilities
2697547
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4208995
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
995003
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
421
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
100
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
177675113
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
171275741
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168533689
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
881960
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4327871
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5439699
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1353095
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2906896
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2714778
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7883413
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2828549
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2498957
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5529291
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6904512
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4181644
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5405853
us-gaap Operating Expenses
OperatingExpenses
8244069
us-gaap Operating Expenses
OperatingExpenses
14787925
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4181644
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5405853
us-gaap Operating Income Loss
OperatingIncomeLoss
-8244069
us-gaap Operating Income Loss
OperatingIncomeLoss
-14787925
CY2023Q2 us-gaap Interest Expense
InterestExpense
5178
CY2022Q2 us-gaap Interest Expense
InterestExpense
3218
us-gaap Interest Expense
InterestExpense
14165
us-gaap Interest Expense
InterestExpense
8823
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
205
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
926
us-gaap Investment Income Interest
InvestmentIncomeInterest
2078
us-gaap Investment Income Interest
InvestmentIncomeInterest
1065
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2615
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3729
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-239301
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7588
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2292
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15816
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-247059
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4189232
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5408145
us-gaap Net Income Loss
NetIncomeLoss
-8259885
us-gaap Net Income Loss
NetIncomeLoss
-15034984
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-136946
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-195351
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4189232
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5545091
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8259885
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15230335
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4189232
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5408145
us-gaap Net Income Loss
NetIncomeLoss
-8259885
us-gaap Net Income Loss
NetIncomeLoss
-15034984
CY2022Q2 fwbi Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
47300
fwbi Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
47300
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
94324
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
97125
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
181755
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
187917
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4283556
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5552570
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8441640
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15270201
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2270922
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2270922
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103844
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103844
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2725755
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2725755
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89015
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89015
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-53.47
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-53.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-171.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-171.55
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2712596
CY2023Q2 fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
-78938
CY2023Q2 fwbi Stock And Exercise Of Warrants Stock During Period Value Cash Net Of Offering Costs
StockAndExerciseOfWarrantsStockDuringPeriodValueCashNetOfOfferingCosts
2239065
CY2023Q2 fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
89
CY2023Q2 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
94324
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
292704
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4189232
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
881960
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-9239785
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
317231
CY2022Q2 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
97125
CY2022Q2 fwbi Warrant Modification
WarrantModification
47300
CY2022Q2 fwbi Deemed Dividend On Warrant Modifications
DeemedDividendOnWarrantModifications
47300
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
374907
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-136946
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5408145
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-14189863
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
3690973
fwbi Stock And Exercise Of Warrants Stock During Period Value Cash Net Of Offering Costs
StockAndExerciseOfWarrantsStockDuringPeriodValueCashNetOfOfferingCosts
2239065
fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
390
fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
181755
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
651020
us-gaap Net Income Loss
NetIncomeLoss
-8259885
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
881960
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-7821550
fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
7972091
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
317231
fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
48482
fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
187917
fwbi Warrant Modification
WarrantModification
47300
fwbi Deemed Dividend On Warrant Modifications
DeemedDividendOnWarrantModifications
47300
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
118999
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
593136
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-195351
us-gaap Net Income Loss
NetIncomeLoss
-15034984
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-14189863
us-gaap Net Income Loss
NetIncomeLoss
-8259885
us-gaap Net Income Loss
NetIncomeLoss
-15034984
us-gaap Depreciation
Depreciation
14637
us-gaap Depreciation
Depreciation
14635
fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
31334
fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
46693
us-gaap Share Based Compensation
ShareBasedCompensation
651020
us-gaap Share Based Compensation
ShareBasedCompensation
593136
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
118999
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-93014
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
70429
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-839094
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-612607
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-31985
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-78228
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-6899
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-9686
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
871155
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1258632
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
159686
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
32982
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
17769
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1410
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5607262
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12497681
fwbi Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
3690973
fwbi Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
8289322
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2239455
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
48482
fwbi Payment Made Related To Acquisition Agreement
PaymentMadeRelatedToAcquisitionAgreement
2414955
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
450016
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
479327
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5480412
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5443522
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-126850
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7054159
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-39516
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1384423
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8248684
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1257573
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1155009
us-gaap Interest Paid Net
InterestPaidNet
14165
us-gaap Interest Paid Net
InterestPaidNet
8823
fwbi Deemed Dividend On Warrant Modifications
DeemedDividendOnWarrantModifications
47300
CY2023Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
181755
CY2022Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
187917
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1200000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176800000
CY2023Q2 fwbi Working Capital Deficiency
WorkingCapitalDeficiency
900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.</p>
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At June 30, 2023 the Company had approximately $1.2 million in one account in the U.S. which was in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.</p>
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1200000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q2 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
153478
CY2022Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
603494
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
58616
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43979
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29202
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43839
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7300
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7300
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14600
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14600
CY2021Q4 us-gaap Goodwill
Goodwill
1911705
CY2022 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-227523
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
0
CY2023Q2 us-gaap Goodwill
Goodwill
1684182
CY2023Q2 fwbi Clinical Trials
ClinicalTrials
301226
CY2022Q4 fwbi Clinical Trials
ClinicalTrials
5340
CY2023Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
178636
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
309867
CY2022Q4 fwbi Consulting Fees
ConsultingFees
4969
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
479862
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320176
CY2023Q2 fwbi Note Payables
NotePayables
153000
CY2022Q4 fwbi Note Payables
NotePayables
603000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2022Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4208995
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
995003
CY2022 fwbi Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
-47000.000
CY2022Q1 fwbi Stocks Issued During Period Shares Common Stock Pre Funded Warrants And Warrants For Cash Net Of Offering Costs
StocksIssuedDuringPeriodSharesCommonStockPreFundedWarrantsAndWarrantsForCashNetOfOfferingCosts
7857
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
288.75
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8000000.0
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
264.60
CY2022Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
fwbi Stock Cancelled During Period Shares Acquisitions
StockCancelledDuringPeriodSharesAcquisitions
2967
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2179798
CY2022Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
19.16
CY2022 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y6M
fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
6389718
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
1.79
fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y10M6D
fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
116
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-773.79
fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
3048825
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-0.65
fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y11M8D
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5520575
CY2023Q2 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
7.85
fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y10M9D
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26089
CY2021Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
1992.90
CY2021 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y11M12D
fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
56795
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
161.70
fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y8M1D
fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
564
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-7755.30
fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
23087
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-2.10
fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y8M1D
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
59233
CY2022Q2 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
732.90
fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y2M4D
fwbi Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
-109
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4363.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3219
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
292704
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
374907
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
651020
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
593136
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
CY2023Q2 fwbi Number Of Real Property Operating Leases
NumberOfRealPropertyOperatingLeases
1
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
35000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
50000
us-gaap Operating Lease Expense
OperatingLeaseExpense
72000
us-gaap Operating Lease Expense
OperatingLeaseExpense
78000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0700
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
42360
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
86202
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
88788
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
60593
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
277943
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
29717
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
248226
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5693089
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
67294
us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.06
CY2023Q2 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
21000
CY2022Q2 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
29000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
47000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
76000

Files In Submission

Name View Source Status
0001410578-23-001882-index-headers.html Edgar Link pending
0001410578-23-001882-index.html Edgar Link pending
0001410578-23-001882.txt Edgar Link pending
0001410578-23-001882-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fwbi-20230630.xsd Edgar Link pending
fwbi-20230630x10q.htm Edgar Link pending
fwbi-20230630xex31d1.htm Edgar Link pending
fwbi-20230630xex31d2.htm Edgar Link pending
fwbi-20230630xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
fwbi-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
fwbi-20230630_def.xml Edgar Link unprocessable
fwbi-20230630_lab.xml Edgar Link unprocessable
fwbi-20230630_pre.xml Edgar Link unprocessable
fwbi-20230630x10q_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending